Tag Archives: halotestin

halotestin

An overdose of insulin causes hypoglycemia, accompanied by the following symptoms: fatigue, increased sweating, tachycardia, pale skin, headache, tremor, vomiting, confusion. Under certain conditions, such as long duration or intensive control of diabetes-harbingers of the symptoms of hypoglycaemia may change.
The light condition of hypoglycemia can usually arrest the ingestion of glucose or sugar. It may be necessary to adjust the insulin dose, diet or physical activity. Moderate hypoglycemia correction can be carried out via intramuscular or subcutaneous injection of glucagon, followed by the ingestion of carbohydrates. Heavy state halotestin of hypoglycemia accompanied by coma, convulsions or neurological disorders, cropped intramuscular / subcutaneous glucagon or intravenous injection of concentrated glucose solution. After regaining consciousness of the patient is necessary to give food rich in carbohydrates, in order to avoid a recurrence of hypoglycemia.

Interaction with other medicinal products
Increase in insulin dosage may be required in the case of the appointment of drugs that increase the level of blood glucose, such as oral contraceptives, steroids, thyroid hormones, danazol, (such as ritodrine, salbutamol, terbutaline), thiazides , Chlorprothixenum, diazoxide, isoniazid, lithium carbonate, nicotinic acid, phenothiazine derivatives. Insulin Dosage reduction may be required in the case of the appointment of drugs that lower blood glucose, such as beta-blockers, ethanol and etanolsoderzhaschie drugs, anabolic steroids, fenfluramine, guanethidine, tetracyclines, oral hypoglycemic drugs, salicylates (eg, aspirin), sulfa antibiotics , certain antidepressants (monoamine oxidase inhibitors), angiotensin converting enzyme inhibitors (captopril, enalapril), octreotide, angiotensin II receptor antagonists.
Beta-blockers, clonidine, reserpine may mask the manifestation of the symptoms of hypoglycemia. Incompatibility . Effects of human insulin when mixed with animal insulin or human insulin, produced by other manufacturers have not been studied.

Special instructions:
Translation of the patient to another type or preparation of insulin with another trade name must be under strict medical supervision. Changes in the activity of the brand halotestin may require dose adjustment.
For some patients, the transition from animal insulin to human insulin may need dose adjustment. This can happen even at the first administration of the preparation of human insulin or gradually over several weeks or months after the transfer.
Symptoms – precursors hypoglycemia during administration of human insulin in some patients may be less pronounced or different from those observed in them with administration of animal insulin When origin normalization of blood glucose levels, for example, as a result of intensive insulin therapy, may disappear all or some of the symptoms – of precursors hypoglycemia than patients should be informed.Symptoms – harbingers of hypoglycemia may change or be less pronounced with prolonged duration of diabetes of diabetic neuropathy or treatment with drugs such as beta-blockers The use halotestin of inadequate dosages or discontinuation of treatment, especially in patients with insulin-dependent diabetes, may lead to hyperglycemia and diabetic ketoacidosis (state, potentially threaten the patient’s life).
insulin requirements may be reduced in case of insufficiency of the pituitary adrenal or thyroid, renal or hepatic insufficiency in some diseases or emotionally straining need for insulin may increase. Insulin dose adjustment may be required with an increase in physical activity or change the normal diet.

Effects on ability to drive vehicles and management mechanisms
During hypoglycemia the patient can reduce the concentration of attention and speed of psychomotor reactions. This can be dangerous in situations where these abilities are particularly necessary halotestin (for example, driving a car or operating machinery).
It should advise patients to take precautions to avoid hypoglycaemia while driving. This is especially important for patients with mild or absent symptoms – harbingers of hypoglycemia or hypoglycemia with frequent development. In such cases, the physician must evaluate the advisability of driving the car by the patient.